ASTER INSIGHTS
LIVE

Serial Number

97849603

Owner

M2GEN, CORP.

Attorney

Karen K. Won

First Use Date

Apr 14, 2023

Filing Date

Mar 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ASTER INSIGHTS Trademark

Serial Number: 97849603 • Registration: 7739987

ASTER INSIGHTS is a trademark filed by M2GEN, CORP. on March 21, 2023. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

M2GEN, CORP. (9 trademarks)

TAMPA, FL 33612

Entity Type: 03

Trademark Details

Filing Date

March 21, 2023

Registration Date

March 25, 2025

First Use Anywhere

April 14, 2023

First Use in Commerce

April 14, 2023

Published for Opposition

April 23, 2024

Goods & Services

Providing an electronic database for the collection and storage of clinical and molecular data derived from a patient, namely, an electronic database featuring medical information in the field of human clinical and molecular data analysis for aiding medical diagnostics, discovery and development and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases; Health care services, namely, providing a database in the field of cancer and other disease medical information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Providing a database in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness, namely, providing medical information data regarding tumor-specific molecular signatures, providing objective medical information data on the effectiveness of a drug and/or diagnostic test, and providing evidence-based treatment protocols by effectively comparing standard treatment therapies with clinical outcomes; collection and analysis of data services in the field of human clinical and molecular data for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases, namely, medical services in the nature of matching particular patients to a particular drug, treatment, therapy or clinical trial by the specific molecular signature of the patient; providing an Internet-accessible website portal featuring medical records for use by physicians, patients and researchers for the storage and accessibility of electronic medical information data in the field of human clinical and molecular data and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness; providing consulting services relating thereto for the aforementioned services.

Providing an electronic database for the collection and storage of clinical and molecular data derived from a patient, namely, an electronic database featuring medical and scientific research information in the field of human clinical and molecular data analysis for aiding medical diagnostics, discovery and development and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases; medical and scientific research data analysis and bioinformatics consulting services relating thereto, namely, computer software consulting, providing online non-downloadable computer software platforms for analyzing medical and scientific research data, and scientific research data analytics consulting in connection with an electronic database for the collection and storage of medical and scientific research information in the fields of clinical and molecular data accumulated for aiding medical diagnostic, discovery and development and prognostics and evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases; providing an Internet-accessible website portal featuring medical records for use by physicians, patients and researchers for the storage and accessibility of electronic medical research data in the field of human clinical and molecular data and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness; providing consulting services relating thereto for the aforementioned services

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 11, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 11, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 11, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 11, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 11, 2025 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 25, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 25, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 28, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 28, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Feb 22, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 22, 2025 AITU
USE AMENDMENT FILED
Dec 11, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 11, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 18, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 21, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 21, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 21, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 21, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 21, 2024 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 28, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 28, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 28, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 19, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 18, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 18, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 18, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 15, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 12, 2023 NWOS
NEW APPLICATION ENTERED
Mar 24, 2023 NWAP